Merck

MRK
147.2401.76% ( -2.640 )
Closed: Oct 22, 16:00:00 (EDT)
Share your thoughts

What's on your mind?

0 / 2,000
12.7k followers · 0 opinions
▲Bullish50%
50%Bearish▼
  • S
    StockMarket.News

    $Moderna(MRNA.US) is now the best performing stock in the S&P 500 this year, up more than 660% in 2026

    That puts a COVID vaccine maker ahead of every AI name in the index, including $Sandisk(SNDK.US) at roughly +566% and $Dell Tech(DELL.US) at roughly +370%. The S&P 500 itself is up about 14%

    The run took off on Aug 19, when $Moderna(MRNA.US) and $Merck(MRK.US) said their personalized mRNA cancer vaccine delayed the return or spread of melanoma in a Phase 3 trial. Back in mid-August the stock was still down close to 90% from its pandemic high

    Last week added two more catalysts. $Moderna(MRNA.US) rejoined the Nasdaq-100, replacing $Warner Bros. Discovery(WBD.US), and the NYT reported the NIH is planning a public-private push to speed up cancer vaccines. Shares gained 18% on the week and closed at their highest level in more than four years

    Full trial data is due Oct 24, and the companies are preparing for regulatory approval next year

    The S&P 500's top performer is a science bet, not an AI trade. Most of this move is priced on data nobody outside $Moderna(MRNA.US) and $Merck(MRK.US) has seen yet, so Oct 24 is when the market finds out whether this is a real oncology platform or a stock that ran too far ahead of the evidence

    Source: StockMarket.News

    图片 1,共 1 张
  • N
    Nancy Pelosi Tracker

    All eyes on SpaceX

    Rep. Maria Elvira Salazar (R) just bought up to $30,000 in SpaceX

    She's the 7th member of Congress to buy $SpaceX(SPCX.US) since the June IPO

    Combined buyers so far: 7

    Combined sellers: 0

    图片 1,共 2 张
    图片 2,共 2 张
  • V
    Vt3

    $Moderna(MRNA.US)

    1️⃣ Exploded high after Moderna and Merck announced positive Ph3 result for their personalised mRNA melanoma cancer therapy, the first mRNA cancer treatment to achieve such a milestone. The news triggered a major short squeeze and a sharp re rating of Moderna’s future prospects.

    2️⃣ I added a position cause the market narrative changed from a declining COVID company to a potential cancer treatment platform. One successful Ph3 trial can reshape future revenues expectations.

    3️⃣ AI stocks depend mainly on earnings, adoption and valuation. MRNA depends on clinical, regulatory and pipeline milestones. In 2 months, I would gauge MRNA by follow through data and institutional support, not hype. 💊🩻🩺

    图片 1,共 1 张
    Trade Showcase: Trade, Show & Earn Rewards!
  • F
    FaithAnchor

    $Moderna(MRNA.US)

    Moderna: Cancer Vaccine Changes the Game — But Don’t Chase the Spike

    Moderna’s 177% single-day surge followed a major breakthrough: its personalised mRNA cancer vaccine, intismeran, met the primary endpoint in a Phase 3 melanoma trial with Merck’s Keytruda, reducing recurrence and cancer spread. (Business Insider⁠)

    This is a genuine validation of personalised cancer vaccines. Earlier Phase 2b data showed a 49% reduction in recurrence/death risk and 59% reduction in distant metastasis/death over five years. (Merck.com⁠) However, detailed Phase 3 data and overall-survival results are still pending, so regulatory and commercial risks remain.

    Fundamentally, Moderna remains loss-making: Q2 revenue was only $100m, with a $800m net loss, although year-end cash guidance improved to $4.7–5.2bn. (Moderna Investors⁠) Valuation has consequently rerated dramatically, while technically the stock is severely extended after the historic gap-up.

    Outlook: HOLD — not Buy at this level. Accumulate only after consolidation or a substantial retracement.

    Option writers: favour 30–60 DTE cash-secured puts, targeting 15–25 delta, rather than chasing covered calls immediately. For bearish traders, consider 30–45 DTE calls around 15–20 delta, but only with defined risk.

    Not financial advice.

    Moderna(MRNA) moderna T CANCER VACCINE BREAKTHROUGH SINGLE DAY GAIN SPARKS : 177
    Trade Showcase: Trade, Show & Earn Rewards!
  • V
    Vt3

    New

    AI Era

    Cool

    Hot Hit

    Ramping

  • V
    Vt3

    Everybody now watching the $Moderna(MRNA.US)

    $Merck(MRK.US)

    Don watch AI anymore 😂💊💊

  • N
    NewUser_oPJWOU

    The 3 local banks have stabilised a little following the previous few days of down sessions for the whole SG market. This is good for the longer scheme of things as historical statistics show that steep rise s n share prices are more likely than not followed by steep drawbacks afterwards. Let them consolidate, though I know many are still buying either for long term or just trying to jump on bandwagon.

    C
    Captain's Watch
    Featured☕️ [Task Coins Giveaway] Daily Market Talk — Moderna Soars 177% on Landmark Cancer Vaccine Win

    Moderna had its best day ever Wednesday: shares soared 177% after its melanoma vaccine, developed with Merck, became the first mRNA cancer therapy to succeed in a Phase 3 trial. Merck rose alongside i...

  • D
    dhighstakes

    $Eli Lilly(LLY.US)

    Merck and moderna are good examples of what it means to get in and be patient. Lily is pumping so much money into research and with AI we might find a cure for diabetes. Get in and be patient. Trials take time for approvals. Diversify from tech!

    图片 1,共 1 张
    Trade Showcase: Trade, Show & Earn Rewards!